Uncategorized

Phase 3 study demonstrates efficacy of new dry eye treatment

by  • 

AMSTERDAM — Liftegrast, a new integrin-antagonist molecule, demonstrated to be well tolerated and effective in relieving dry eye symptoms in a phase 3 study.  “Chronic inflammation is widely accepted as responsible for the cycle that causes many types of dry eye disease.  Liftegrast blocks T-cell activation, proliferation, adhesion and migration, a key step in the chronic dry eye inflammatory cycle,” John Sheppard, MD, said at the European Society of Cataract and Refractive Surgeons meeting.

Read more →

Peer-reviewed

Metamorphopsia and Optical Coherence Tomography Findings After Rhegmatogenous Retinal Detachment Surgery – Corrected Proof

by  • 

Purpose: To investigate the relationship between metamorphopsia and macular morphologic changes after successful repair of rhegmatogenous retinal detachment (RD).Design: Prospective, interventional, consecutive study.Methods: The study included 129 eyes of 129 patients who had undergone successful retinal reattachment surgery. The severity of metamorphopsia was recorded using M-CHARTS and foveal microstructure was assessed with spectral-domain optical coherence tomography (OCT) at 6-12 months postoperatively.Results: The mean metamorphopsia score was 0.30 ± 0.46, and 50 of 129 patients (39%) had metamorphopsia. Metamorphopsia was more severe in eyes with macula-off rhegmatogenous RD than those with macula-on (P < .001). Eighteen of 50 eyes with metamorphopsia exhibited abnormal structures (Read more...)